Cidara Therapeutics Inc [CDTX] stock is trading at $73.49, down -2.62%. An important factor to consider is whether the stock is rising or falling in short-term value. The CDTX shares have gain 13.57% over the last week, with a monthly amount glided 10.73%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Citizens JMP started tracking the stock with Mkt Outperform rating on March 12, 2025, and set its price target to $46. RBC Capital Mkts started tracking the stock assigning a Outperform rating and suggested a price target of $34 on December 13, 2024. Guggenheim initiated its recommendation with a Buy and recommended $33 as its price target on November 08, 2024. H.C. Wainwright upgraded its rating to Buy for this stock on August 14, 2024, but kept the price target unchanged to $24.
Cidara Therapeutics Inc [CDTX] stock has fluctuated between $10.14 and $75.64 over the past year. Currently, Wall Street analysts expect the stock to reach $69 within the next 12 months. Cidara Therapeutics Inc [NASDAQ: CDTX] shares were valued at $73.49 at the most recent close of the market. An investor can expect a potential drop of -6.11% based on the average CDTX price forecast.
Analyzing the CDTX fundamentals
Cidara Therapeutics Inc [NASDAQ:CDTX] reported sales of 0.00M for the trailing twelve months, which represents a drop of -100.00%. To continue investigating profitability, this company’s Return on Assets is posted at -0.17, Equity is -0.4 and Total Capital is -0.26. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.0.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 71.86 points at the first support level, and at 70.23 for the second support level. However, for the 1st resistance point, the stock is sitting at 75.56, and for the 2nd resistance point, it is at 77.63.
Ratios To Look Out For
For context, Cidara Therapeutics Inc’s Current Ratio is 16.45. On the other hand, the Quick Ratio is 16.45, and the Cash Ratio is 15.8.
Transactions by insiders
Recent insider trading involved Davarpanah Nicole Negar, Chief Medical Officer, that happened on Sep 11 ’25 when 474.0 shares were sold. Director, RA CAPITAL MANAGEMENT, L.P. completed a deal on Jun 26 ’25 to buy 2.27 million shares. Meanwhile, Director Mineo Chrysa bought 2270.0 shares on Jun 02 ’25.
